DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Mowbray, CEORCID logo; Braillard, SORCID logo; Glossop, PAORCID logo; Whitlock, GA; Jacobs, RTORCID logo; Speake, J; Pandi, B; Nare, B; Maes, L; Yardley, V; Freund, Y; Wall, RJORCID logo; Carvalho, S; Bello, D; Van den Kerkhof, M; Caljon, G; Gilbert, IHORCID logo; Corpas-Lopez, V; Lukac, I; Patterson, S; Zuccotto, FORCID logo and Wyllie, SORCID logo (2021). DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. [Dataset]. ACS Publications, Washington, DC, USA. https://doi.org/10.1021/acs.jmedchem.1c01437.s004
Copy

DNDI-6148 has been declared a preclinical candidate for the treatment of visceral leishmaniasis. This collection contains documentation (S1), string data for all compounds (S2), DNDI-6148 rat and dog pharmacokinetic data (S3) and Compound 23 docked into LdCPSF3 (S4). Files may be accessed through the Collection Record held on Figshare.

Keywords

Visceral leishmaniasis; Parasitic diseases; Benzoxaborole chemotype; Antileishmanial activity; DNDI-6148


Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core (with Type as Type) MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON METS MODS RDF+N3 RDF+N-Triples RDF+XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export